Skip header information|
Wadsworth Center Home - Science in the Pursuit of Health|
Main Body

Investigators and Program Directors

Anne Messer

Anne Messer

Research Scientist, Wadsworth Center, Molecular Genetics
Professor, School of Public Health, Biomedical Sciences

Ph.D., University of Oregon
Postdoctoral training, Harvard Medical School

E-mail:messer@wadsworth.org

<< Research Interests

Select Publications

  • McLear, J.A., D. Lebrecht, A. Messer and W.J. Wolfgang (2008) Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington’s disease. FASEB J 22, 2003-11.
  • Lynch, S.M., C. Zhou and A. Messer (2008) An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity, J Mol Biol 377, 136-147.
  • Kvam, E. and A. Messer (2007) Engineered antibody fragments as potential therapeutics against misfolded proteins in neurodegenerative diseases In: Handbook of Neurochemistry and Molecular Neurobiology, 3rd Edition (Volume 24), in press.
  • Goryunov D., A. Adebola, J.J. Jefferson, C.L. Leung, A. Messer and R. K. Liem. (2007) Molecular characterization of the genetic lesion in Dystonia musculorum (dt-Alb) mice. Brain Res 6, 179-187.
  • Messer, A. and J. McLear (2006) The Therapeutic Potential of Intrabodies in Neurological Disorders: Focus on Huntington's and Parkinson's Diseases. BioDrugs 20, 327-333.
  • Miller, T.W. and A. Messer (2005) Intrabody applications in neurological disorders: progress and future prospects. Mol Therapy 12, 394-401.
  • Wolfgang W, T. Miller, J.M. Webster, J. Huston, L. Thompson, J.L. Marsh and A. Messer (2005) Suppression of Huntington’s Disease pathology in Drosophila by intracellular antibodies. Proc Natl Acad Sci USA 102, 11563-11568.
  • Colby, D.W., Y. Chu, J. Cassady, M. Duennwald, H. Zazulak, J.M. Webster, A. Messer, S. Lindquist, V.M. Ingram and K.D. Wittrup (2004) Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single domain intrabody. Proc Natl Acad Sci USA 101, 17616-17621.
  • Miller T.W., C. Zhou, S. Gines, M.E. MacDonald, N.D. Mazarakis, G.P. Bates, J.S. Huston and A. Messer (2005) A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's Disease. Neurobiol Dis 19, 47-56.
  • Zhou, C., S. Emadi, M.R. Sierks and A. Messer (2004) A human anti-alpha-synuclein intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Therapy 10, 1023-1031.
  • Colby, D.W., P. Garg, T. Holden, G. Chao, J.M. Webster, A. Messer, V.M. Ingram and K.D. Wittrup (2004) Development of a Human Variable Light Chain Domain Intracellular Antibody against Huntingtin via Yeast Surface Display. J Mol Biol 342, 901-912.
  • Shirley T.L. and A. Messer (2004) Early postnatal Purkinje cells from staggerer mice undergo aberrant development in vitro with characteristic morphologic and gene expression abnormalities. Dev Brain Res 152, 153-157.
  • Emadi, S., R. Liu, B. Yuan, P. Schulz, C. McAllistar, Y. Lyubchenko, A. Messer and M. R. Sierks (2004) Inhibiting aggregation of alpha-synuclein with human single-chain antibody fragments. Biochem 43, 2871-2878.
  • Bolivar, V. J., K. Manley and A. Messer (2004) Early exploratory behavior abnormalities in R6/1 Huntington’s disease transgenic mice. Brain Res 1005, 29-35.
  • Murphy, R.C. and A. Messer (2004) A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Mol Brain Res 121, 141-145.
  • Bolivar, V. J., K. Manley and A. Messer (2003) Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav Neurosci 117, 1233-1242.
  • Miller, T.W., T.L. Shirley, W.J. Wolfgang, X. Kang and A. Messer (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Therapy 7, 572-579.
  • Bolivar, V., J. S. Ganus and A. Messer (2002) The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Res 937, 74-82.
  • Chu-LaGraff ,Q., X. Kang and A. Messer (2001) Expression of the Huntington’s Disease transgene in neural stem cell cultures from R6/2 transgenic mice. Brain Res Bull 56, 307-312.
  • Murphy, R.C. and A. Messer (2001) Gene transfer methods for CNS organotypic cultures: A comparison of three nonviral methods. Mol Ther 3, 113-121.
  • Lecerf, J.M., T.L. Shirley, Q. Zhu, A. Kazantsev, P. Amersdorfer, D.E. Housman, A. Messer and J.S. Huston (2001) Human single- chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington’s Disease. Proc Natl Acad Sci USA 98, 4764-4769.
  • Messer, A. and X. Kang (2000) Control of transcription in the RORa-staggerer mutant mouse cerebellum: Glutamate receptor delta2 mRNA. Int J Dev Neurosci 18, 663-668.
  • Bibb J.A., Z. Yan, P. Svenningsson, G.L. Snyder, V.A. Pieribone, A. Horiuchi, A.C. Nairn, A. Messer and P. Greengard (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 97, 6809-6814.
  • Manley, K., T.L. Shirley, L. Flaherty and A. Messer (1999) Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Gene 23, 471-473.

Contact Information

E-mail:messer@wadsworth.org.